About Proton-transporting V-type ATPase complex assembly regulator TMEM9
Proton-transporting V-type ATPase complex assembly regulator TMEM9 (TMEM9) is a protein
from Homo sapiens identified by UniProt accession
Q9P0T7, 183 residues long.
MolForge cross-references it against 0 known binders and
12 disease associations.
Target properties
| Protein name | Proton-transporting V-type ATPase complex assembly regulator TMEM9 |
|---|
| UniProt accession | Q9P0T7 |
|---|
| Gene | TMEM9 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 183 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (12)
Diseases linked to this target (Open Targets).
- diffuse plaque measurement · score 0.16
- lung adenocarcinoma · score 0.07
- neoplasm · score 0.06
- hepatocellular carcinoma · score 0.02
- breast cancer · score 0.02
- hemoglobin measurement · score 0.02
- cancer · score 0.02
- short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome · score 0.01
- colorectal cancer · score 0.00
- non-small cell lung carcinoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9P0T7-F1 | alphafold | PREDICTED | 72.81 | — |
Amino-acid sequence (183 residues)
MKLLSLVAVV GCLLVPPAEA NKSSEDIRCK CICPPYRNIS GHIYNQNVSQ KDCNCLHVVE PMPVPGHDVE AYCLLCECRY EERSTTTIKV IIVIYLSVVG ALLLYMAFLM LVDPLIRKPD AYTEQLHNEE ENEDARSMAA AAASLGGPRA NTVLERVEGA QQRWKLQVQE QRKTVFDRHK MLS
Explore Proton-transporting V-type ATPase complex assembly regulator TMEM9 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets